PL2338487T3 - Terapia skojarzona z inhibitorami PARP - Google Patents

Terapia skojarzona z inhibitorami PARP

Info

Publication number
PL2338487T3
PL2338487T3 PL11157696T PL11157696T PL2338487T3 PL 2338487 T3 PL2338487 T3 PL 2338487T3 PL 11157696 T PL11157696 T PL 11157696T PL 11157696 T PL11157696 T PL 11157696T PL 2338487 T3 PL2338487 T3 PL 2338487T3
Authority
PL
Poland
Prior art keywords
combination therapy
parp inhibitors
parp
inhibitors
therapy
Prior art date
Application number
PL11157696T
Other languages
English (en)
Inventor
Wolfgang Wernet
Thomas D Penning
Vincent L Giranda
Original Assignee
Abbvie Bahamas Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bahamas Ltd filed Critical Abbvie Bahamas Ltd
Publication of PL2338487T3 publication Critical patent/PL2338487T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11157696T 2006-01-17 2007-01-17 Terapia skojarzona z inhibitorami PARP PL2338487T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75944506P 2006-01-17 2006-01-17
US80411206P 2006-06-07 2006-06-07
US85004206P 2006-10-06 2006-10-06
US82926106P 2006-10-12 2006-10-12
US86751806P 2006-11-28 2006-11-28
EP11157696.3A EP2338487B1 (en) 2006-01-17 2007-01-17 Combination therapy with PARP inhibitors
EP07716699A EP1976515A2 (en) 2006-01-17 2007-01-17 Combination therapy with parp inhibitors

Publications (1)

Publication Number Publication Date
PL2338487T3 true PL2338487T3 (pl) 2014-03-31

Family

ID=38141258

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11157696T PL2338487T3 (pl) 2006-01-17 2007-01-17 Terapia skojarzona z inhibitorami PARP

Country Status (14)

Country Link
US (4) US20070265324A1 (pl)
EP (3) EP2329818A1 (pl)
JP (4) JP5289060B2 (pl)
CN (1) CN101370497B (pl)
CA (1) CA2635691C (pl)
DK (1) DK2338487T3 (pl)
ES (1) ES2437132T3 (pl)
HR (1) HRP20131180T1 (pl)
ME (1) ME02121B (pl)
PL (1) PL2338487T3 (pl)
PT (1) PT2338487E (pl)
RS (1) RS53082B (pl)
SI (1) SI2338487T1 (pl)
WO (1) WO2007084532A2 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234318T3 (es) 1998-11-03 2005-06-16 ABBOTT GMBH & CO. KG 2-fenil-benzimidazoles sustituidos, su preparacion y uso.
US7728026B2 (en) * 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
NZ565654A (en) 2005-07-18 2010-10-29 Bipar Sciences Inc Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
WO2007041357A1 (en) * 2005-09-29 2007-04-12 Abbott Laboratories 1h-benzimidazole-4-carboxamides substituted with phenyl at the 2-position are potent parp inhibitors
ATE461923T1 (de) * 2005-11-15 2010-04-15 Abbott Lab Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ES2385849T3 (es) * 2006-05-02 2012-08-01 Abbott Laboratories Las 1H-bencimidazol-4-carboxamidas substituidas son potentes inhibidores de la PARP
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
CA2662337A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
JP2011503111A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
JP2011521618A (ja) * 2008-02-04 2011-07-28 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ仲介疾患を診断および治療する方法
JP2013532703A (ja) * 2010-08-03 2013-08-19 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｐａｒｐ−１阻害剤および抗新生物剤を含む治療用組合せ
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
WO2012141990A1 (en) 2011-04-11 2012-10-18 Abb Vie Inc. Parp inhibitors for the treatment of cipn
US20130310625A1 (en) 2012-05-15 2013-11-21 Abbvie Inc. Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
CN104230896A (zh) * 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
MX2016007433A (es) 2013-12-10 2016-09-13 Abbvie Inc Veliparib en combinacion con carboplatino para el tratamiento de cancer de mama triple negativo.
CA2934552C (en) 2014-01-14 2021-03-30 Nektar Therapeutics Combination-based treatment method
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
PL3337467T3 (pl) 2015-08-20 2021-06-14 Ipsen Biopharm Ltd. Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
IL257149B2 (en) 2015-08-21 2024-11-01 Ipsen Biopharm Ltd Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
CN105712937B (zh) * 2016-02-28 2019-02-22 河北宁格生物医药科技有限公司 一种治疗转移性肿瘤的化合物及其用途
EP3535026A1 (en) 2016-11-02 2019-09-11 Ipsen Biopharm Limited Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
GB201709076D0 (en) * 2017-06-07 2017-07-19 Inst Of Cancer Research: Royal Cancer Hospital Parp inhibitors for use in methods of treating cancer
KR20200121800A (ko) * 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US11590130B2 (en) 2018-04-05 2023-02-28 Noviga Research Ab Combinations of a tubulin polymerization inhibitor and a poly (ADP-ribose) polymerase (PARP) inhibitor for use in the treatment of cancer
CN109232540A (zh) * 2018-06-15 2019-01-18 深圳市坤健创新药物研究院 一种取代苯并咪唑衍生物及应用
CN108997320A (zh) * 2018-08-30 2018-12-14 深圳市坤健创新药物研究院 一种含氟取代苯并咪唑衍生物及应用
BR112021017350A2 (pt) * 2019-03-27 2021-11-16 Daiichi Sankyo Co Ltd Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
MY209459A (en) 2019-07-10 2025-07-09 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
CA3146560A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
CN114053415B (zh) * 2020-07-30 2024-06-18 江苏天士力帝益药业有限公司 Tsl-1502复方药物组合
US12293220B2 (en) 2022-04-21 2025-05-06 Dell Products L.P. Context-driven framework to migrate the applications and its dependencies by analyzing the relationships
CA3172480A1 (en) 2022-04-27 2023-10-27 Susanne KOSSATZ Combination treatment of small-cell lung cancer
CN118615452A (zh) * 2023-03-07 2024-09-10 中国科学院分子细胞科学卓越创新中心 Dna损伤药物联合化疗
US12566633B2 (en) 2023-04-20 2026-03-03 Dell Products L.P. Method and system for managing resource utilization of applications
US12292781B2 (en) 2023-04-21 2025-05-06 Dell Products L.P. Method and system for managing power consumption for devices

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100447539B1 (ko) * 1995-08-02 2004-11-10 뉴캐슬 유니버시티 벤처스 리미티드 벤조이미다졸화합물과이를포함하는제약학적조성물및이화합물을이용한치료방법
WO1997007804A1 (en) * 1995-08-28 1997-03-06 Schering Corporation Combination therapy for advanced cancer comprising temozolomide and cisplatin
KR20000068392A (ko) * 1997-07-02 2000-11-25 리더 존 피. 개질된 열가소성 비닐리덴 플루오라이드계 수지로부터의 플루오로중합체 분산 피복물
NZ511825A (en) * 1998-11-27 2003-08-29 Basf Ag Substituted benzimidazoles and their use as parp inhibitors
HRP20010573B1 (en) * 1999-01-11 2006-04-30 Agouron Pharmaceuticals Tricyclic inhibitors of poly(adp-ribose) polymerases
CN1345240A (zh) * 1999-03-30 2002-04-17 先灵公司 用替莫唑胺改善癌症治疗
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
WO2001021615A1 (fr) * 1999-09-17 2001-03-29 Yamanouchi Pharmaceutical Co., Ltd. Dérivés de benzimidazole
AU2003229953A1 (en) * 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2520997A1 (en) * 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ES2396334T3 (es) * 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
JP2008519584A (ja) * 2004-11-09 2008-06-12 シェーリング コーポレイション 患者のｍｇｍｔレベルに基づいて癌を処置するための、テモゾロミドの改良された投薬養生法
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
EP1908481A1 (en) * 2005-06-24 2008-04-09 Ono Pharmaceutical Co., Ltd. Agent for reduction of bleeding in cerebrovascular disorder

Also Published As

Publication number Publication date
JP2015187114A (ja) 2015-10-29
PT2338487E (pt) 2013-12-16
EP1976515A2 (en) 2008-10-08
CN101370497A (zh) 2009-02-18
SI2338487T1 (sl) 2014-01-31
WO2007084532A3 (en) 2007-09-07
US20120045524A1 (en) 2012-02-23
HRP20131180T1 (hr) 2014-01-31
ME02121B (me) 2014-06-30
US20110151023A1 (en) 2011-06-23
JP5289060B2 (ja) 2013-09-11
CN101370497B (zh) 2010-11-17
JP2013136605A (ja) 2013-07-11
JP2009523801A (ja) 2009-06-25
EP2338487A1 (en) 2011-06-29
US20110152336A1 (en) 2011-06-23
DK2338487T3 (da) 2013-12-09
EP2338487B1 (en) 2013-09-11
RS53082B (sr) 2014-06-30
EP2329818A1 (en) 2011-06-08
CA2635691A1 (en) 2007-07-26
JP2017160216A (ja) 2017-09-14
JP6147799B2 (ja) 2017-06-14
US20070265324A1 (en) 2007-11-15
WO2007084532A2 (en) 2007-07-26
ES2437132T3 (es) 2014-01-09
CA2635691C (en) 2013-10-29

Similar Documents

Publication Publication Date Title
SI2338487T1 (sl) Kombinacijska terapija z inhibitorji PARP
IL196559A0 (en) Combination therapy
GB0609492D0 (en) Therapeutic agents
GB2436010B (en) Therapy device
ZA200904860B (en) Combination therapy with angiogenesis inhibitors
EP2032168A4 (en) COMBINED THERAPY BASED ON CAPECITABINE
EP2035005A4 (en) THERAPY BASED ON CYTOKINE INHIBITORS
GB0608928D0 (en) Therapeutic agents
IL196556A0 (en) Combination therapy
GB0601962D0 (en) Therapeutic agents
IL199992A0 (en) Combination therapy
HRP20130041T8 (en) Therapeutic agents
EP2054061A4 (en) COMBINATION THERAPY
GB0723747D0 (en) Therapeutic agents
GB0616214D0 (en) Therapeutic Agents
IL198026A0 (en) Sequential combination therapy
ZA200902203B (en) Combination therapy
GB0611152D0 (en) Therapeutic agents
EP2211863A4 (en) COMBINATION THERAPY
GB0620059D0 (en) Therapeutic agents
GB0620818D0 (en) Therapeutic agents
GB0700284D0 (en) Combination therapy
GB2441007B (en) Auricular therapy
GB0609676D0 (en) Therapeutic agents
GB0723748D0 (en) Therapeutic agents